The Board of HaemaLogiX Ltd has appointed non-executive director, Dr, John Cullity, as Chairman of the Company to hold office through the next phase of the Company transformation, which was initiated earlier this year with the announcement of our new CEO.
Read article +HaemaLogiX is pleased to announce that our Chief Manufacturing and Development Officer, Tertia Dex, has been invited to speak at the 2nd Annual Australia Biologics Festival #ABF 2024 held February 20-21 in Melbourne.
Read article +HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023.
Read article +HaemaLogiX’s Israeli patent “Kappa Myeloma Antigen Chimeric Receptors and Uses Thereof” was granted in Israel on 2 August 2023.
Read article +HaemaLogix Chief Scientific Officer, Dr. Rosanne Dunn, was invited to present at Cell and Gene Therapy World Asia, held on 14-15 September in Singapore.
Read article +